Avitia

Executive Summary

Avitia is a San Francisco-based biotechnology company developing a single-cell functional genomics platform integrated with AI-driven discovery tools to decode immune responses and identify novel therapeutic targets. Founded in 2020, the company has raised $50 million and operates in the platform stage with 50-200 employees. Its technology combines high-throughput single-cell profiling with machine learning to map immune cell states, enabling precision immunology and target identification for autoimmune diseases, cancer immunotherapy, and infectious diseases. By focusing on the intersection of AI, immunology, and genomics, Avitia addresses the critical need for functional understanding of immune heterogeneity, offering a proprietary data-generation engine that can deconvolute complex immune mechanisms. The platform's value lies in its ability to generate actionable insights from functional genomic data, potentially accelerating drug discovery and development pipelines for partners. While still in the platform-building phase, Avitia's approach could position it as a key enabler for pharma companies seeking to leverage single-cell technologies for target discovery and patient stratification.

Upcoming Catalysts (preview)

• Q3 2026Pharmaceutical Partnership or Collaboration60% success
• Q4 2026Launch of AI-Driven Target Discovery Platform70% success
• Q2 2027Series B Funding Announcement80% success